advertisement
Abstract #8525 Published in IGR 5-1
Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys
Chien FY; Wang RF; Mittag TW; Podos SMArchives of Ophthalmology 2003; 121: 87-90
OBJECTIVE: To evaluate the effects of WIN 55212-2, a cannabinoid receptor agonist, on intraocular pressure (IOP) and aqueous humor dynamics in normal monkeys and monkeys with glaucoma. METHODS: IOP was measured prior to and up to six hours after the topical administration of WIN 55212-2 to one eye of five normal monkeys and to the glaucomatous eye of eight monkeys with unilateral laser-induced glaucoma. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in six normal monkeys before and after treatment. RESULTS: In normal monkeys, a single dose of WIN 55212-2 reduced IOP for four, five, or six hours, with a maximum reduction of 1.4 ± 0.4 (mean ± SEM) mmHg, 2.9 ± 0.4 mmHg, and 3.4 ± 0.6 mmHg following the 0.07%, 0.2%, and 0.5% concentrations, respectively (p = 0.08). In eight glaucomatous monkey eyes, the ocular hypotensive effect was maintained for five days with twice-daily administration of 0.5% WIN 55212-2. Outflow facility was unchanged (p = 0.34) and aqueous humor flow was decreased by 18% (p = 0.04) in the treated eyes compared with vehicle-treated contralateral control eyes in normal monkeys. CONCLUSIONS: WIN 55212-2, a cannabinoid agonist at the CB(1) receptor, reduces IOP in both normal and glaucomatous monkey eyes. A decrease of aqueous flow appears to account for the IOP reduction in normal monkey eyes. CLINICAL RELEVANCE: Cannabinoid agonists at the CB(1) receptor, a new class of antiglaucoma agents that is different from currently used clinical drugs, may have clinical potential.
Dr. F.Y. Chien, Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY 10029, USA
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
